Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S319000, C548S132000, C549S407000, C549S426000, C549S471000
Reexamination Certificate
active
07998968
ABSTRACT:
A compound represented by the formula (I):wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula:is a group represented by the formula:R2 is a group represented by the formula:R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. For example, the compound may be substituted pyrimidines and pharmaceutical compositions of the formula (I) where X=—CR3; X1=—CR2 or —NR2; and X2=—CR5 or —NR5. The compound of the present invention is useful as a drug for the prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases.
REFERENCES:
patent: 5162326 (1992-11-01), Naka et al.
patent: 5166206 (1992-11-01), Allen et al.
patent: 5183899 (1993-02-01), Naka et al.
patent: 5243054 (1993-09-01), Naka et al.
patent: 5254574 (1993-10-01), Binder et al.
patent: 5304565 (1994-04-01), Morimoto et al.
patent: 5411980 (1995-05-01), Ashton et al.
patent: 5472967 (1995-12-01), Hoornaert et al.
patent: 5496835 (1996-03-01), Kubo et al.
patent: 5500427 (1996-03-01), Kubo et al.
patent: 5565464 (1996-10-01), Salimbeni et al.
patent: 5583141 (1996-12-01), Naka et al.
patent: 5807878 (1998-09-01), Corbier et al.
patent: 5877121 (1999-03-01), Andree et al.
patent: 2001/0020100 (2001-09-01), Manning et al.
patent: 2004/0039038 (2004-02-01), Bernardon et al.
patent: 2008/0207654 (2008-08-01), Kuroita et al.
patent: 0 685 467 (1995-12-01), None
patent: 2 078 764 (1997-05-01), None
patent: 2 174 513 (1998-12-01), None
patent: WO 92/17469 (1992-10-01), None
patent: WO 94/08990 (1994-04-01), None
patent: WO 94/21629 (1994-09-01), None
patent: WO 95/16677 (1995-06-01), None
patent: WO 96/07647 (1996-03-01), None
patent: WO 02/12210 (2002-02-01), None
patent: WO 2006/074057 (2006-07-01), None
patent: WO 2006/100520 (2006-09-01), None
patent: WO 2007/003271 (2007-01-01), None
patent: WO 2008/062905 (2008-05-01), None
U.S. Appl. No. 12/516,099, filed Nov. 21, 2007, Kuroita et al.
Benson et al., “Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist with Selective PPARy-Modulating Activity,” Hypertension, May 2004, 43:993-1002.
Ferrari et al., “Development of Tetrazole Bioisosteres in Angiotensin II Antagonists,” Bioorganic & Medicinal Chemistry Letters, 1994, 4(1):45-50.
International Search Report and Written Opinion of Aug. 24, 2009, in corresponding PCT/JP2009/058796, 18 pages.
Jordan, V.C., Nature Reviews: Drug Discovery, 2003, 2:205.
Schupp et al., “Regulation of Peroxisome Proliferator-Activated Receptor γActivity by Losartan Metabolites,” Hypertension, Mar. 2006 Part II, 47:586-589.
Vippagunta et al., Advanced Drug Delivery Reviews, 2001, 48:18.
Wolff, Manfred E., Ed., Burger's Medicinal Chemistry and Drug Discovery—Fifth Edition, New York, John Wiley & Sons, 1996, 1:975-976.
Notice of Opposition filed Oct. 22, 2009, in corresponding Costa Rican Application No. 10847, 9 pages.
English translation of Notice of Opposition filed Oct. 22, 2009, in corresponding Costa Rican Application No. 10847, 10 pages.
Notice of Opposition against Ecuadorian Patent Application No. SP-09-9461, dated Mar. 4, 2010, 10 pages, with English translation, 8 pages.
Hoyer et al., “Molecular, pharmacological and functional diversity of 5-HT receptors,” Pharmacology, Biochemistry and Behavior, 2002, 71:533-554.
WHO Drug Information, 2006, 20(2):61-162.
Search Report issued Aug. 17, 2010, in corresponding Georgian patent application, with English translation, 8 pages.
Asano Kouhei
Fuji Koji
Igawa Hideyuki
Kuroita Takanobu
Maekawa Tsuyoshi
Foley & Lardner LLP
Takeda Pharmaceutical Company Limited
Willis Douglas M
Wilson James O
LandOfFree
Substituted pyrimidines and [1,2, 4] triazoles and the use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrimidines and [1,2, 4] triazoles and the use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrimidines and [1,2, 4] triazoles and the use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2772895